Evaluating comparative effectiveness of Pfizer-BioNtech and Moderna vaccines among US veterans

By | December 3, 2021
A new study provided evidence of a lower 24-week risk of COVID-19–related outcomes among recipients of the mRNA-1273 vaccine, compared to their counterparts who received the BNT162b2 vaccine.